摘要
目的观察评价米曲菌胰酶片对肝硬化消化不良患者的临床疗效。方法选取2019年12月至2020年8月在保定市第一中心医院治疗的80例合并消化不良症状的患者,采用随机数字表法分为实验组和对照组,每组40例。对照组采用常规对症治疗;实验组采用保肝、针对并发症及口服米曲菌胰酶片治疗(2片/次,3次/d,疗程4周)。米曲菌胰酶片药物每片含米曲菌霉提取物24 mg,胰酶220 mg。比较两组治疗2周和4周后消化不良症状总疗效评价;比较两组治疗4周后SF-36生活质量问卷测评结果;比较两组治疗前后肝功能监测指标、Child-Pugh评分情况。结果 (1)实验组治疗第2、4周后腹胀症状积分较对照组降低(P<0.05)。(2)实验组米曲菌胰酶片治疗4周后消化不良症状总有效率高于对照组(P<0.05)。(3)实验组治疗后总胆红素、谷丙转氨酶及Child-Pugh分级评分较对照组降低(P<0.05)。(4)两组治疗4周后生理机能、生理智能、躯体疼痛、一般健康状况、精力、社会功能、情感智能及精神健康比较,差异有统计学意义(P<0.05)。结论肝硬化伴有消化不良症状的患者加用米曲菌胰酶片治疗,其在临床症状改善方面可以获得良好疗效。
【Objective】To evaluate the efficacy and safety of combizym in cirrhotic patients with dyspepsia.【Methods】Eight y patients with liver cirrhosis complicated with abdominal distension who were admitted to our hospital from December 2019 to August 2020 were selected and enrolled in this study.The patients were divided into treatment group(40 cases)and control group(40 cases)by completely random method.The control group was treated with conventional symptomatic therapy;the treatment group,on the basis of the control group,was further given combizym tablets(2 tablets tid,with a meal or post meal,for 4 weeks)on the basis of regular treatment.The total curative effect evaluation of dyspepsia symptoms between the two groups of patients after 2 weeks and 4 weeks of treatment,the evaluation results of the SF-36 quality of life questionnaire between the two groups of patients after 4 weeks of treatment,the liver function monitoring indicators and Child-Pugh of the two groups before and after treatment were compared.【Results】In the treatment group,after 2 weeks and 4 weeks of treatment,the score of dyspeptic symptoms was lower than that in the control group(P<0.05);the total effective rate of dyspeptic symptoms improvement in the treatment group was 95%,which in the control group was 65%,and the difference was statistically significant(P<0.05).After 4 weeks of treatment,the quality of life score of the experimental group was significantly higher than that of the control group.The Child-Pugh scores of bilirubin and transaminase in the experimental group decreased significantly higher than those in the control group.【Conclusion】Combizym is effective and safe in the treatment of cirrhotic patients with dyspeptic symptoms.
作者
任振宇
郝英霞
REN Zhenyu;HAO Yingxia(Chengde Medical College,Chengde,Hebei 067000,China;Department of Gastroenterology,the First Central Hospital of Baoding,Baoding,Hebei 071000,China)
出处
《中国医学工程》
2021年第7期85-88,共4页
China Medical Engineering
关键词
肝硬化
米曲菌胰酶片
消化不良
疗效
liver cirrhosis
oryz-aspergillus enzyme and pancreatin tablet
dyspepsia
efficacy
